US Stocks Move | RXO (RXO.US) surges nearly 23% in pre-market after being acquired by C.H. Robinson Logistics (CHRW.US) for $5.8 billions
C.H. Robinson Logistics (CHRW.US) has agreed to acquire trucking brokerage company RXO (RXO.US) for approximately $5.8 billions, aiming to strengthen the logistics operations of the merged company.
According to Jinse Finance, C.H. Robinson Worldwide (CHRW.US) has agreed to acquire trucking brokerage RXO (RXO.US) for approximately $5.8 billion, in a move aimed at strengthening the logistics operations of the combined company. In a statement issued by both companies on Monday, RXO shareholders will receive $17.25 in cash and 0.0856 C.H. Robinson Worldwide shares for each RXO share, equivalent to a total consideration of about $30.25 per share—a 29% premium compared to RXO's closing price last Friday. Before the U.S. market opened on Monday, at the time of reporting, C.H. Robinson Worldwide fell nearly 9%, while RXO rose almost 23%.
The transaction is expected to be completed in the first half of 2027. C.H. Robinson Worldwide aims to diversify its business through this deal and fully leverage RXO's strengths in rapid delivery and last-mile logistics. The acquirer plans to use artificial intelligence to improve operations and achieve $300 million in cost savings within two years.
The freight industry is struggling with high costs, including record diesel prices. This merger also comes after a U.S. Supreme Court ruling earlier this year that dealt a significant blow to the truck brokerage market—if a carrier’s driver is involved in a traffic accident, the brokerage could face lawsuits.
C.H. Robinson Worldwide stated it will fund the cash portion of the transaction through new debt financing and has signed a fully underwritten bridge loan agreement with Morgan Stanley Senior Funding. RXO shareholders are expected to own 11% of the combined company after the transaction concludes.
Morgan Stanley serves as financial advisor to C.H. Robinson Worldwide, while Goldman Sachs acts as financial advisor to RXO.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley Analyst Says SpaceX Stock Price Could Double
Getlink reports 550,000,000 shares outstanding, 642,851,718 total voting rights as of Sept. 30, 2026
Getlink disclosed 550,000,000 ordinary shares outstanding as of Sept. 30, 2026. Theoretical voting rights totaled 642,851,718. Exercisable voting rights stood at 635,332,063. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Getlink SE published the original content used to generate this news brief via Business Wire (Ref. ID: 202610051200BIZWIRE_USPR_____20261005_BW048564) on October 05, 2026, and is solely responsible for the information contained therein.
Stifel raises the S&P 500 year-end target to 7,900 points
Reuters, October 5 – Stifel has raised its year-end target for the S&P 500 .SPX benchmark index from 7,800 to 7,900, citing expectations of stronger corporate earnings and gains driven by AI spending, despite a worsening macroeconomic environment. Key details include: In a report released on Sunday, the brokerage said robust government spending and AI investments are propelling profit growth. However, it also noted that strong economic activity is keeping interest rates elevated for a longer period. The revised target is 1.9% higher than the index’s current level. Despite rising energy costs, persistent inflation, high bond yields, and cooling enthusiasm for AI, U.S. equities remain resilient. The brokerage stated that sticky inflation is once again dominating market movements, strong economic data is putting pressure on stocks, and the safe-haven appeal of bonds has diminished. “Capital expenditures and operating leverage in the tech sector continue to drive margin expansion in the S&P 500,” the report said. Stifel's forecast is slightly below the consensus among brokerages, many of which predict the S&P 500 will close at 8,000 points or higher by the end of 2026 (link), with the bull market extending into next year. (For ease of non-English speakers, Reuters provides automated translations of its reports into several other languages. Since automated translations may contain errors or lack required context, Reuters does not guarantee the accuracy of the automated translation and provides it solely for readers’ convenience. Reuters will not be liable for any damage or loss arising from the use of the automated translation feature.)
European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading
11:12 AM EDT, 10/05/2026 (MT Newswires) -- European equities traded in the US as American depositary receipts opened the week lower late Monday morning, declining 0.14% to 1,883.96 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by lender Banco Santander (SAN) and brewing company Anheuser-Busch InBev (BUD), which advanced 3.2% and 0.8% respectively. They were followed by 3D printer company Materialise (MTLS) and internet browser company Opera (OPRA), which were up 0.6% and 0.3% respectively. The decliners from continental Europe were led by biopharmaceutical company Nokia (NOK) and biopharmaceutical company Cellectis (CLLS), which lost 3.2% each. They were followed by biopharmaceutical company DBV Technologies (DBVT) and petroleum refiner Equinor (EQNR), which decreased 0.9% and 0.4%, respectively. The gainers from the UK were led by biopharmaceutical company Bicycle Therapeutics (BCYC) and software firm Endava plc (DAVA), which climbed 17% and 1.6% respectively. They were followed by medical device maker Smith & Nephew (SNN) and biotech firm Trinity Biotech (TRIB), which increased 1.2% and 1.4% respectively. The decliners from the UK and Ireland were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which dropped 3.9% and 1.4% respectively. They were followed by hospitality company InterContinental Hotels Group (IHG) and pharmaceutical company GSK (GSK), which fell 1.1% and 1% respectively.
